vs
安费诺（APH）与徕博科（LH）财务数据对比。点击上方公司名可切换其他公司
安费诺的季度营收约是徕博科的1.8倍（$6.4B vs $3.5B），安费诺净利率更高（18.6% vs 4.7%，领先13.9%），安费诺同比增速更快（49.1% vs 5.6%），安费诺自由现金流更多（$1.5B vs $490.3M），过去两年安费诺的营收复合增速更高（40.6% vs 5.2%）
安费诺是一家总部位于美国的电子零部件制造企业，核心产品涵盖电子连接器、光纤连接器、同轴电缆等各类线缆及互连系统，是全球互连解决方案领域的主流供应商，品牌名称源自其前身American Phenolic Corp的名称缩写组合。
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
APH vs LH — 直观对比
营收规模更大
APH
是对方的1.8倍
$3.5B
营收增速更快
APH
高出43.5%
5.6%
净利率更高
APH
高出13.9%
4.7%
自由现金流更多
APH
多$978.2M
$490.3M
两年增速更快
APH
近两年复合增速
5.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $6.4B | $3.5B |
| 净利润 | $1.2B | $164.7M |
| 毛利率 | 38.2% | 28.2% |
| 营业利润率 | 26.8% | 7.6% |
| 净利率 | 18.6% | 4.7% |
| 营收同比 | 49.1% | 5.6% |
| 净利润同比 | 60.2% | 14.9% |
| 每股收益（稀释后） | $0.93 | $1.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APHLH
| Q4 25 | $6.4B | $3.5B | ||
| Q3 25 | $6.2B | $3.6B | ||
| Q2 25 | $5.7B | $3.5B | ||
| Q1 25 | $4.8B | $3.3B | ||
| Q4 24 | $4.3B | $3.3B | ||
| Q3 24 | $4.0B | $3.3B | ||
| Q2 24 | $3.6B | $3.2B | ||
| Q1 24 | $3.3B | $3.2B |
净利润APHLH
| Q4 25 | $1.2B | $164.7M | ||
| Q3 25 | $1.2B | $261.1M | ||
| Q2 25 | $1.1B | $237.9M | ||
| Q1 25 | $737.8M | $212.8M | ||
| Q4 24 | $746.1M | $143.4M | ||
| Q3 24 | $604.4M | $169.3M | ||
| Q2 24 | $524.8M | $205.3M | ||
| Q1 24 | $548.7M | $228.0M |
毛利率APHLH
| Q4 25 | 38.2% | 28.2% | ||
| Q3 25 | 38.1% | 28.8% | ||
| Q2 25 | 36.3% | 29.7% | ||
| Q1 25 | 34.2% | 28.3% | ||
| Q4 24 | 34.3% | 26.9% | ||
| Q3 24 | 33.6% | 27.6% | ||
| Q2 24 | 33.6% | 28.8% | ||
| Q1 24 | 33.4% | 28.2% |
营业利润率APHLH
| Q4 25 | 26.8% | 7.6% | ||
| Q3 25 | 27.5% | 11.1% | ||
| Q2 25 | 25.1% | 11.2% | ||
| Q1 25 | 21.3% | 9.7% | ||
| Q4 24 | 22.1% | 6.5% | ||
| Q3 24 | 20.3% | 7.7% | ||
| Q2 24 | 19.4% | 9.2% | ||
| Q1 24 | 21.0% | 10.1% |
净利率APHLH
| Q4 25 | 18.6% | 4.7% | ||
| Q3 25 | 20.1% | 7.3% | ||
| Q2 25 | 19.3% | 6.7% | ||
| Q1 25 | 15.3% | 6.4% | ||
| Q4 24 | 17.3% | 4.3% | ||
| Q3 24 | 15.0% | 5.2% | ||
| Q2 24 | 14.5% | 6.4% | ||
| Q1 24 | 16.9% | 7.2% |
每股收益（稀释后）APHLH
| Q4 25 | $0.93 | $1.98 | ||
| Q3 25 | $0.97 | $3.12 | ||
| Q2 25 | $0.86 | $2.84 | ||
| Q1 25 | $0.58 | $2.52 | ||
| Q4 24 | $0.16 | $1.72 | ||
| Q3 24 | $0.48 | $2.00 | ||
| Q2 24 | $0.41 | $2.43 | ||
| Q1 24 | $0.87 | $2.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.4B | $532.3M |
| 总债务越低越好 | $14.6B | — |
| 股东权益账面价值 | $13.4B | $8.6B |
| 总资产 | $36.2B | $18.4B |
| 负债/权益比越低杠杆越低 | 1.09× | — |
8季度趋势，按日历期对齐
现金及短期投资APHLH
| Q4 25 | $11.4B | $532.3M | ||
| Q3 25 | $3.9B | $598.1M | ||
| Q2 25 | $3.2B | $647.3M | ||
| Q1 25 | $1.7B | $369.4M | ||
| Q4 24 | $3.3B | $1.5B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.3B | $265.1M | ||
| Q1 24 | $2.0B | $99.3M |
总债务APHLH
| Q4 25 | $14.6B | — | ||
| Q3 25 | $7.1B | — | ||
| Q2 25 | $7.1B | — | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | $6.5B | — | ||
| Q3 24 | $5.1B | — | ||
| Q2 24 | $5.0B | — | ||
| Q1 24 | $3.6B | — |
股东权益APHLH
| Q4 25 | $13.4B | $8.6B | ||
| Q3 25 | $12.5B | $8.7B | ||
| Q2 25 | $11.5B | $8.5B | ||
| Q1 25 | $10.3B | $8.3B | ||
| Q4 24 | $9.8B | $8.1B | ||
| Q3 24 | $9.5B | $8.2B | ||
| Q2 24 | $9.0B | $8.0B | ||
| Q1 24 | $8.7B | $8.0B |
总资产APHLH
| Q4 25 | $36.2B | $18.4B | ||
| Q3 25 | $27.1B | $18.3B | ||
| Q2 25 | $25.7B | $18.1B | ||
| Q1 25 | $22.9B | $17.6B | ||
| Q4 24 | $21.4B | $18.4B | ||
| Q3 24 | $19.6B | $18.6B | ||
| Q2 24 | $18.6B | $16.7B | ||
| Q1 24 | $16.7B | $16.5B |
负债/权益比APHLH
| Q4 25 | 1.09× | — | ||
| Q3 25 | 0.57× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.66× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.56× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.7B | $614.2M |
| 自由现金流经营现金流 - 资本支出 | $1.5B | $490.3M |
| 自由现金流率自由现金流/营收 | 22.8% | 13.9% |
| 资本支出强度资本支出/营收 | 3.9% | 3.5% |
| 现金转化率经营现金流/净利润 | 1.44× | 3.73× |
| 过去12个月自由现金流最近4个季度 | $4.4B | $1.2B |
8季度趋势，按日历期对齐
经营现金流APHLH
| Q4 25 | $1.7B | $614.2M | ||
| Q3 25 | $1.5B | $387.2M | ||
| Q2 25 | $1.4B | $620.6M | ||
| Q1 25 | $764.9M | $18.5M | ||
| Q4 24 | $847.1M | $777.2M | ||
| Q3 24 | $704.0M | $277.3M | ||
| Q2 24 | $664.1M | $561.1M | ||
| Q1 24 | $599.5M | $-29.8M |
自由现金流APHLH
| Q4 25 | $1.5B | $490.3M | ||
| Q3 25 | $1.2B | $280.5M | ||
| Q2 25 | $1.1B | $542.7M | ||
| Q1 25 | $576.3M | $-107.5M | ||
| Q4 24 | $647.3M | $665.1M | ||
| Q3 24 | $474.0M | $161.5M | ||
| Q2 24 | $522.8M | $432.9M | ||
| Q1 24 | $505.2M | $-163.6M |
自由现金流率APHLH
| Q4 25 | 22.8% | 13.9% | ||
| Q3 25 | 19.6% | 7.9% | ||
| Q2 25 | 19.8% | 15.4% | ||
| Q1 25 | 12.0% | -3.2% | ||
| Q4 24 | 15.0% | 20.0% | ||
| Q3 24 | 11.7% | 4.9% | ||
| Q2 24 | 14.5% | 13.4% | ||
| Q1 24 | 15.5% | -5.2% |
资本支出强度APHLH
| Q4 25 | 3.9% | 3.5% | ||
| Q3 25 | 4.2% | 3.0% | ||
| Q2 25 | 5.3% | 2.2% | ||
| Q1 25 | 3.9% | 3.8% | ||
| Q4 24 | 4.6% | 3.4% | ||
| Q3 24 | 5.7% | 3.5% | ||
| Q2 24 | 3.9% | 4.0% | ||
| Q1 24 | 2.9% | 4.2% |
现金转化率APHLH
| Q4 25 | 1.44× | 3.73× | ||
| Q3 25 | 1.18× | 1.48× | ||
| Q2 25 | 1.30× | 2.61× | ||
| Q1 25 | 1.04× | 0.09× | ||
| Q4 24 | 1.14× | 5.42× | ||
| Q3 24 | 1.16× | 1.64× | ||
| Q2 24 | 1.27× | 2.73× | ||
| Q1 24 | 1.09× | -0.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APH
| Communications Solutions Segment | $3.5B | 54% |
| Harsh Environment Solutions Segment | $1.7B | 26% |
| Sales Channel Through Intermediary | $1.4B | 21% |
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
